Comparative Pharmacology
Head-to-head clinical analysis: PIFELTRO versus RILPIVIRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIFELTRO versus RILPIVIRINE HYDROCHLORIDE.
PIFELTRO vs RILPIVIRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective allosteric inhibitor of HIV-1 capsid protein, interfering with multiple steps of the viral life cycle including capsid assembly, nuclear import, and virion maturation.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. It binds to HIV-1 reverse transcriptase, causing a conformational change that inhibits enzyme activity and prevents viral RNA conversion to DNA.
200 mg orally once daily, taken with or without food.
25 mg orally once daily with a meal.
None Documented
None Documented
12-13 hours in healthy subjects; clinically, supports once-daily dosing.
Terminal elimination half-life is approximately 34.6 hours (range 25–56 hours), supporting once-daily dosing. Steady-state reached in ~2 weeks.
Primarily hepatic metabolism with subsequent biliary/fecal elimination. 86% of a single oral dose recovered in feces (mostly as metabolites) and <1% unchanged in urine.
Primarily hepatic metabolism (CYP3A4), with 85% of dose excreted in feces (unchanged drug and metabolites) and 6.1% in urine (unchanged drug). Renal elimination of unchanged drug is <1%.
Category C
Category A/B
NNRTI
NNRTI